<SEC-DOCUMENT>0001213900-23-002796.txt : 20230113
<SEC-HEADER>0001213900-23-002796.hdr.sgml : 20230113
<ACCEPTANCE-DATETIME>20230113161529
ACCESSION NUMBER:		0001213900-23-002796
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230113
DATE AS OF CHANGE:		20230113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Can-Fite BioPharma Ltd.
		CENTRAL INDEX KEY:			0001536196
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-262055
		FILM NUMBER:		23528938

	BUSINESS ADDRESS:	
		STREET 1:		10 BAREKET STREET, KIRYAT MATALON
		STREET 2:		P.O. BOX 7537
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951778
		BUSINESS PHONE:		972 39241114

	MAIL ADDRESS:	
		STREET 1:		10 BAREKET STREET, KIRYAT MATALON
		STREET 2:		P.O. BOX 7537
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951778
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>ea171649-424b3_canfite.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-262055</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; background-color: white"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; background-color: white"><B>(To Prospectus dated January 14, 2022)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>180,000,000 Ordinary
Shares represented by 600,000 American Depositary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">This
prospectus supplement, or the Supplement, modifies, supersedes and supplements certain information contained in, and should be read in
conjunction with, that certain prospectus supplement filed with the Securities and Exchange Commission, or the SEC, by Can-Fite Biopharma
Ltd., the Company, dated January 14, 2022, or the Prospectus, related to the resale by the selling shareholders named therein of up to
190,500,000 ordinary shares, par value NIS 0.25 per share of the Company, or ordinary shares, represented by 635,000 American Depository
Shares, or ADSs, consisting of (i) 180,000,000 ordinary shares represented by 600,000 ADSs issuable upon the exercise of warrants issued
in a private placement in December 2021, or the December 2021 Private Placement, at an original exercise price of $20.00 per share, or
the December 2021 Investor Warrants, and (ii) 10,500,000 ordinary shares represented by 35,000 ADSs issuable upon the exercise of placement
agent warrants issued in connection with the December 2021 Private Placement. The December 2021 Investor Warrants have been amended as
described below under &ldquo;Amendments to Existing Warrants.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The ADSs are listed on NYSE
American under the symbol &ldquo;CANF.&rdquo; On January 10, 2023, the closing price of our ADSs on the NYSE American was $6.57 per ADS.
Our ordinary shares also trade on the Tel Aviv Stock Exchange, or TASE, under the symbol &ldquo;CFBI&rdquo;. On January 10, 2023, the
last reported sale price of our ordinary shares on the TASE was NIS 8.30 or $2.3642 per share (based on the exchange rate reported by
the Bank of Israel on the same day).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">The
information contained in this Supplement modifies and supersedes, in part, the information in the Prospectus. This Supplement is not complete
without, and may not be delivered or used except in connection with, the Prospectus. Any information that is modified or superseded in
the Prospectus shall not be deemed to constitute a part of the Prospectus, except as modified or superseded by this Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">We
may amend or supplement the Prospectus from time to time by filing amendments or supplements as required. You should read the entire Prospectus
and any amendments or supplements carefully before you make an investment decision. <FONT STYLE="background-color: white">This Supplement
amends only those sections of the Prospectus contained in this Supplement; all other sections of the prospectus supplement remain unchanged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white"><B>Investing
in our securities involves risks. See &ldquo;Risk Factors&rdquo; on page 3 of the Prospectus and in the documents incorporated by reference
into the Prospectus, including the risks described under &ldquo;Risk Factors&rdquo; in our Annual Report on Form 20-F for the year ended
December 31, 2021.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this Supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">Effective
as of January 9, 2023, the ratio of our ADSs to ordinary shares changed from one (1) ADS representing thirty (30) ordinary shares to a
new ratio of one (1) ADS representing three hundred (300) ordinary shares, which ratio change had the same effect as a one-for-ten reverse
ADS split, or the ADS Ratio Change. All share and per share prices in this Supplement have been adjusted to reflect the ADS Ratio Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">You
should carefully consider the risk factors set forth in or incorporated by reference into the Prospectus, as well as the other information
contained in or incorporated by reference into this Supplement and the Prospectus. This Supplement, the Prospectus and documents incorporated
therein by reference contain forward-looking statements regarding events, conditions, and financial trends that may affect our plan of
operation, business strategy, operating results, and financial position. You are cautioned that any forward-looking statements are not
guarantees of future performance and are subject to risks and uncertainties. Actual results may differ materially from those included
within the forward-looking statements as a result of various factors. Cautionary statements in the &ldquo;Risk Factors&rdquo; section
of the Prospectus and the reports incorporated by reference therein identify important risks and uncertainties affecting our future, which
could cause actual results to differ materially from the forward-looking statements made or included in this Supplement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>AMENDMENTS TO EXISTING
WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; background-color: white">This Supplement is being
filed to disclose the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On January 11, 2023, in connection
with a securities purchase agreement, dated as of January 11, 2023, entered into by the Company with an institutional investor, or the
RD Purchase Agreement, the Company filed a prospectus supplement, or the Registered Direct Prospectus Supplement, and the accompanying
base prospectus with the SEC under the Company&rsquo;s registration statement on Form F-3 (Registration No. 333- 249063). Pursuant to
the RD Purchase Agreement and the Registered Direct Prospectus Supplement, the Company offered and sold an aggregate of 90,000,000 ordinary
shares represented by 300,000 ADSs and pre-funded warrants to purchase up to 210,000,000 ordinary shares represented by 700,000 ADSs,
or the Registered Direct Offering. Pursuant to the RD Purchase Agreement, the Company also offered and sold in a private placement to
the institutional investor in the Registered Direct Offering unregistered Series A warrants to purchase up to an aggregate of 300,000,000
ordinary shares represented by 1,000,000 ADSs and unregistered Series B warrants to purchase up to an aggregate of 300,000,000 ordinary
shares represented by 1,000,000 ADSs. The Series A warrants have an exercise price $6.00 per ADS, became exercisable immediately upon
issuance and have a term of five and one-half years from the date of issuance and the Series B warrants have an exercise price $5.50 per
ADS, became exercisable immediately upon issuance and have a term of 20 months from the date of issuance. The purchase price for one ADS
and associated warrants was $5.50 and for one pre-funded warrant and associated warrants was $5.499. The Registered Direct Offering closed
on January 3, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On January 11, 2023, concurrently
with the Registered Direct Offering, the Company entered into a securities purchase agreement, dated as of January 11, 2023, with the
institutional investor that participated in the Registered Direct Offering, for the purchase and sale of unregistered pre-funded warrants
to purchase up to an aggregate of 109,091,100 ordinary shares represented by 363,637 ADSs, unregistered Series A warrants to purchase
up to an aggregate of 109,091,100 ordinary shares represented by 363,637 ADSs and unregistered Series B warrants to purchase up to an
aggregate of 109,091,100 ordinary shares represented by 363,637 ADSs, or the Private Placement Offering. The terms of the Series A warrants
and the Series B warrants in sold in the Private Placement Offering are identical to those sold in the Registered Direct Offering. The
purchase price for one pre-funded warrant and associated warrants was $5.499.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In connection with the Registered
Direct Offering and the Private Placement Offering, we entered into Warrant Amendment Agreement, or the Warrant Amendment Agreement, with
the investor in the offerings to amend the December 2021 Investor Warrants, in consideration for their purchase of approximately $7.5
million of our securities in the Registered Direct Offering and the Private Placement Offering. Pursuant to the Warrant Amendment Agreement,
effective upon the closing of the Registered Direct Offering and the Private Placement Offering, such December 2021 Investor Warrants
held by the investor in the Registered Direct Offering and the Private Placement Offering were amended to reduce the exercise price per
ADS to $5.50 per share. No changes have been made to the other warrants sold in the December 2021 Private Placement to purchase up to
an aggregate of 10,500,000 ordinary shares represented by 35,000 ADSs, which shares may be resold under the Prospectus, as amended by
this Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">The date of this Prospectus
Supplement is January 13, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !+ 2L# 2(  A$! Q$!_\0
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M_C&;5;**37[AHWN(U93''R"P!'W:YSQ!_P C-J__ %_3_P#HQJATG_D-:?\
M]?47_H8KLY(\NPSZ&^+>MZGH'A.VO-)O'M+AKU(V= I)4HY(Y![@?E7C'_"R
M_&G_ $,-S_W[C_\ B:]:^.O_ "(UI_V$8_\ T7)7SW44(IQU0(ZK_A9?C3_H
M8;G_ +]Q_P#Q-'_"R_&G_0PW/_?N/_XFJ_@[PC<^,]7FTZUNHK9XH#.7E4L"
M RKCC_>KM_\ A0NL?]!NQ_[]/52=.+LP.0_X67XT_P"AAN?^_<?_ ,36WIWC
MWQ3-X.\07DFMSM<VT]FL,A1,H':3<!\N.=H_*M3_ (4+K'_0;L?^_3U6\0>
M;SP5\/\ 63=WL%U]LN;3;Y2%=NQGSG/^^/RJ7*F[) <S_P ++\:?]##<_P#?
MN/\ ^)K6T'Q_XLNH-<:?7+AS!I<DT1*)\CB6(!ON^C'\Z\_KI_!.G7>KW&N:
M?80F>[GTB58HPP7<?-B.,D@#IW-:RA%+8!__  LOQI_T,-S_ -^X_P#XFC_A
M9?C3_H8;G_OW'_\ $U/_ ,*J\<?]"_)_X%0?_%U4U'X>^+=(TZ>_O]&>"U@7
M=+(;B)MH]<!R3^ H_=^0$G_"R_&G_0PW/_?N/_XFC_A9?C3_ *&&Y_[]Q_\
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M.DD;%65@<@@CD$'O7J-7C8H^T**^0_\ A*O$G_0QZQ_X'R__ !5'_"5^)/\
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M%-U9-6;"XM%%%0!Y/XR^$<GB?Q1<:Q::K%:"X1/,C> O\ZC;D$,.P7]:P_\
MA0-__P!##;?^ C?_ !=>Z45HJLTK)A<\+_X4#?\ _0PVW_@(W_Q=;_@KX2W?
MA3Q-#J\VL0W*1QNGEI;E"=PQUW&O5:*'5FU9L+A69K.E6FMZ3<:9?1^9;7*%
M'7O[$>A!P0>Q K3HK,#PH_ *^#';XBMRN>";0YQ_WW4MG\"K^UOK:X.OV["&
M5)"HM6&=K X^][5[ABC%:>VGW'<Y#Q]X0F\::!#IL-XEHT=RL_F/&7! 5AC
M(_O?I7G/_"@K_P#Z&&V_\!&_^+KT7XB^)+[PKX3EU33U@:X2:- )T++AC@\
MC^=<E?>)_B7I.@_V[=6/AZ:P6-)76'S-^QL<\M[^_P!#1!S2T8&CX ^&-UX*
MUZ?49M5ANUEMF@") 4()96SDL?[OZUZ8*X35/%NHS>&-!UC2'TNT_M&2(R)J
M4P0!&4DJA)7<V>GKZ5U6HZMI^DP+-J5]:V<3':'N)5C!/H"3UJ)7;NQ&C7+>
M.O"\OB_PV^E0W:6KM*DGF.A<?*<XP"*TSJUK>:-/J&F7=O=1)$[I+#()$) /
M<&O,= \7_$WQ%H)UG3;+0)H 67RV2178KU &_'ZTXI[H#._X4%?_ /0PVW_@
M(W_Q==-X#^%MUX-\1-JLVK0W2FV>#RT@*'+,ISDL?[OZU4G^*-_<_"Z3Q/86
MUO'J$%TMM-%*K/%NX)*\@X*L#UXSCG&3WMCXATRYGAL&U2Q.IM&K/:+.OF [
M<D;,Y]ZJ4ZEK,9NUA>*M%?Q%X:OM)CG6![J+8)&7<%Y!SC(STJSJ6O:3HQ0:
MGJ=E9&3[@N9UC+?3)YI?[9TO^R_[3_M*S_L_K]K\]?*ZX^_G'7CKUJ%=:B/'
M?^%!7_\ T,-M_P" C?\ Q=;/A#X0WGAGQ78:S+K4-PEJSDQ+;E2VZ-DZ[C_>
MS^%>@GQ-H"O,G]N:<&@C664&Z3]VAQAFYX!W+R?[P]12KXBT5[V*Q35[!KR5
M0T=N+E"[@C<"%SDY'(]15NK-JS&;59VL6#:GHE_8)((VNK:2$.1D*64C./QJ
M*TU[1]2NY;2QU2SNKF'/F10W"NZ8.#D Y'/%,O\ Q/H.EW/V74-;TZUN, ^5
M/=(C8/0X)S6=F(\C'P!O\?\ (PVW_@(W_P 72_\ "@;_ /Z&&V_\!&_^+KVR
M*5)HDEB=7C<!E93D$'H0>]<;X[\6ZCX7O?#\-A%:NNHW@@F,Z,Q"Y4?+AA@_
M,>N:U56HW9,=SA/^%!7_ /T,-M_X"-_\71_PH*__ .AAMO\ P$;_ .+KW2N(
M\._$+3_$/BG5=*CDMHX[5D2T?[0K->'YR[(!U4!0>,\<G%)5:C"YP7_"@K__
M *&&V_\  1O_ (NO3/!_AR;PMX7L]&>5+IK<R$S>3C=ND9^F[_:Q^%3:OXHT
MVQM]0MH=2L#JL%O)(EH9U,FY4+ %,Y[9QZ5E>"_$%YXD\)66K7Z6JW,YDWB.
MW.WY9&48S(3T4=ZIRG-:@=Q1116(@HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /.OC7Q\.+CO\ Z1#_ .A5QNM^"9(_ DE_/XWOYHX[1;@6-W<%
MH7(4,L87=ZX XZXXKUCQ/H]AKVC2V.I0&:V,L9*"1DY#<<J0:Y"T^%?@MIUW
M:,3S_P _<W_Q=:0^$9ROB?5I-<^&O@J_EM8;9FU-(_*A7;& F]!M'887(':M
M:>RM-?\ CS>6'B"..XMK6Q4V%O./D<[48_*>&Y:4X_V?]FNXU[PSH^H:?I-C
M<62_9;6Y1X(HW:-8RJ$#&TC@#MTJIXY\+:+KFDW%_J-@DUW:)^YF#LC*,],J
M1D<G@Y'-%P.*\/PV^D_$SQEI.B831QIS220QG,<<P5.!Z$%G&.W(_AP,WX=^
M'?%>L^"A_97BP:7ITDLB- MLK,#QN(?AAGV(Q7J/A[PQHVAZ'):Z;8I!%=&,
M3X9F:0,JY!8DG'S-@9XR<8JQX6T:PT#1UL=,@,%L)W(0R,_)Z\L2:.:R8'G7
MCCPK:>#O@U+IMH[RG[5'+-,PP9)"P!..PP  /0#J>:K>-_#ND^'M,\%W6EV,
M-M="^@#7$:@22' ;+MU8Y&<GW]:]2\4Z-8:]H4UCJ4!FMC)&2@D9.01W4@U5
MUW0-,U>QLH[ZW,J64\<EN/-==C!>#P1G\<T1=[7 XS6Q8ZY\2]0LM*\+6FJZ
MO;VR)<W.K7)^S1#"D;8B&SC<.5 Y+>I)X_204^"WC&+,91-33 B)*??A^[GG
M' Q[5Z1XJ\':#J/BVRN;FQ)FNP([AXYY(S*N0N&VL,\<?0 =A5Z3P3X>M=*O
M]+@T_P NQO[B-[B!9I K$'(Q\WRC('"X&!CIQ36P'%ZCX<TG2O@<^HVEDB7]
MYIMJ]Q<<EI"[QNV2?<_RK%\6>'-)L?ACX.O;6RB@O;N2W\^Z1<2.9(B[$MU/
MS8(STQQBO7;K1-.NO#$.@S6Y;3/LD4?D^8P^52FT;@=W&/6J>K^&M)O=#TW2
M[BU+V5A)#]FC\UQLVQ$+R#DX'J32BPN<AJ&BZ=X?^-/A.'2;*&SC>VD5T@0*
M&PD@R<=3CJ3R>*R;]+'7HO%]_H'A;3GMHWF-WJNJW+.^]5)8PI@LA[CD#[O3
M&!ZGJ6B:?=>*-(U>:W+7UK'*(9?,8;05.> <'J>HKG[GP#X8E\9R&32U99_]
M(EB,TGEO)ECDINVGGG&,4)]P+/PA+-\,=(+$D@S@9/0">0 ?E6-\82!J?@TD
M@ :F"2?]Y*[;PQI=GHFC0:?I\316L9DV1F1GQE\GEB3U)/XU0\8>'-)\1P0)
MJMJ;A8&D,8\UTP2!G[I&?QI+XQ'1K>6S,%6XA+$X #C)->1^ ]'L8?'/C=[7
M3X//TR4#3P$'[DGSEPGID8%:=A\._"MC?:??6VE;+F*X@DC?[1*=K"52#@MC
MK6K+X9T>#XFP:M%9[;UB9#()'P6964G;G'(]O?K1:UT,X#P;HGAW4OA-KFK:
ME#;SZC^_>6[FPTL4@7<A5CR"20?]HGG/2N\^$O\ R3+2?K/_ .CY*KWO@#PL
M_BRYF;2(R64S,GF/Y9?:3G9NV]><8QGFNJ\+Z+8Z7X?@LK*.2&WB>4(@F<XS
+(Q/4^I-5S: ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
